This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Alnylam Presents New Pre-clinical Data On ALN-AAT, An RNAi Therapeutic Targeting Alpha-1-Antitrypsin (AAT) For The Treatment Of AAT Deficiency Liver Disease

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with ALN-AAT, an RNAi therapeutic targeting alpha-1 antitrypsin (AAT) in development for the treatment of liver disease associated with AAT deficiency. These data were presented in a poster entitled “Developing an RNAi Therapeutic for Liver Disease Associated with Alpha-1-Antitrypsin Deficiency” at the 64 th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD, “The Liver Meeting”) held November 1 – 5, 2013 in Washington, D.C. AAT deficiency liver disease is a rare genetic disorder, with the most common mutation being in the “Z-allele,” which results in the accumulation of the mutant AAT protein (Z-AAT) in liver tissue with subsequent liver injury, fibrosis, and, in some cases, hepatocellular carcinoma. There are approximately 12,000 people in the U.S. and E.U. with liver pathology associated with AAT deficiency.

Alnylam scientists and collaborators presented new results in a transgenic mouse model of Z-AAT protein over-expression showing that subcutaneous administration of a GalNAc-siRNA targeting AAT led to rapid, potent, dose-dependent, and durable knockdown of AAT of greater than 90%, as well as a significant reduction in fibrosis and the incidence of liver tumors. ALN-AAT is a program in the company’s “Alnylam 5x15” product development and commercialization strategy, by which the company aims to advance five RNAi therapeutic programs toward genetically validated disease targets into clinical development, including programs in advanced stages, by the end of 2015.

“We are excited about the potential for RNAi therapeutics for the treatment of liver disease associated with AAT deficiency, a rare genetic disorder. AAT deficiency liver disease is caused by the mutant ‘Z allele’ of the AAT gene, whose protein misfolds, accumulates in liver cells, and causes cellular damage. Our therapeutic hypothesis is that an RNAi therapeutic that silences the mutant Z-AAT will prevent the development and/or progression of liver disease,” said Rachel Meyers, Ph.D., Vice President of Research and RNAi Lead Development at Alnylam. “Our new pre-clinical data with a GalNAc-siRNA conjugate against AAT demonstrate rapid, potent, dose-dependent, and durable knockdown of AAT to greater than 90% resulting in a significant reduction of liver fibrosis and tumor formation. If these results extend in clinical studies, we believe that ALN-AAT could become an important treatment option for the management of disease in people with AAT deficiency.”

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,440.59 -127.94 -0.73%
S&P 500 2,067.64 -12.01 -0.58%
NASDAQ 5,039.7760 -48.8540 -0.96%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs